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Lymphoreticular tumors have been observed in mice with an experimentally 
induced immunological disorder, the graft-versus-host reaction (GVHR)  (1, 2). 
Young adult (BALB/cJ × A/J)F1 hybrid (CAF1) mice in which a protracted form 
of GVHR is induced by the injection of immunocompetent  BALB/cJ cells develop 
tumors al~r some months. The incidence of tumors increases with age. Thus, at 
12 mo the incidence is 27% and by 18 mo it is 55%, compared with a 5% incidence 
among control CAF1 mice (2). Tumorigenesis in the GVHR appears to be due to 
endogenous murine leukemia virus (MuLV) activated by the immune disturb- 
ance, because cell-free extracts prepared from the reticular tissues of GVHR- 
CAF1 mice:  (a)  induce lymphorecticular tumors in syngeneic recipients;  (b) 
contain MuLV complement-fLxing antigens and beth types of naturally occur- 
ring mouse-tropic MuLV,  namely, B-tropic  and N-tropic MuLV  (3). Experi- 
ments to confirm that endogenous MuLV is indeed responsible for tumor induc- 
tion in this experimental model have been hampered by the latency of the agent. 
Cell-free extracts from GVHR-CAF1 mice cause tumors in only a  minority of 
recipients aider at  least  15  mo  (3). However, serial  in vivo  passage of such 
extracts has  resulted in  preparations that  cause tumors  in  most recipients 
within 12 mo (4). These preparations contain B-tropic MuLV, and when inocu- 
lated into infant syngeneic mice, B-tropic MuLV is found in the reticular tissues 
as early as 2 wk thereafter. The virus persists in the reticular tissues throughout 
the  latent  period  and  is  present  in  the  tumors  that  subsequently develop. 
However, when the same preparations are injected into young adult recipients, 
there may be transient B-tropic MuLV replication, but the virus subsequently 
disappears from the reticular tissues and no tumors develop (4). 
To understand the mechanism by which the oncogenic potential of endoge- 
nous B-tropic MuLV is expressed in the GVHR model, we asked when B-tropic 
MuLV first appears and how efficiently it replicates. Hirsch and his colleagues 
reported the rapid activation of N-tropic MuLV in young CAF1 mice after the 
injection of BALB/c spleen cells (5). However, their observations were limited to 
the first 4 mo of the GVHR. We have looked for the presence of both B- and N- 
tropic MuLV throughout the entire period between initiation of the GVHR and 
* Supported by U. S. Public Health Service grants AI-08614,  CA-15557,  CA-16038, and by grant 
IM-19  from the American Cancer Society; also grants HL-16126,  NSF BMS 74-08742,  and GM- 
12607. 
1060  THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  • VOLUME  145, 1977 ARMSTRONG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
I00 
GVHR-CAFI/J  0" 
i¢1 
U 
50 
F,.- 
N  o 
O 
0. 
I 
""  100 
> 
N  50 
(7)xil2)  (6)  (12)  (7)  (6)  (12)  (8)  (3)  (15) (3)  (10)  (7)  (3)  (3)  (5)  (5) 
,'aJl~  0  J  "  , 
.,,.,/  :  .'- 
,,/  -  - 
--ill,=,,,,~_llll  I  I  ~  I  ~o"  I  I  I  I  I  • 
NCAFI/JO" 
(7) (3)  (s)  (5)  (4)  (6)  (s)  (4)  (6)  (s)  (6) 
1061 
I  ]  I  I  i  I  I  0  ,.L._ ~_  J_~_  ~_ ~m" 
8  16  --  24  --  ~2  40  48  56  64  72  80 
AGE  (weeks) 
Fro.  1.  Age-related  appearance  of B-  and  N-tropic  MuLV  among  CAF1/J  male  mice 
undergoing a graft-versus-host reaction (GVHR-CAFIJ~) and among normal control CAFIJ 
male mice  (NCAF~/J~).  Percentage of mice with B-tropic (0-0),  with N-tropic  (m---m) 
MuLV.  (. ×. ) number of mice tested for MuLV. 
development  of tumors and have found that the GVHR accelerates the induction 
of both viruses in CAF: mice and preferentially enhances the replication of B- 
tropic MuLV. 
Materials and Methods 
Induction  of GVHR.  A  GVHR was induced in 7-wk-old  (BALB/cJ  ×  A/J)F1  hybrid (CAF1) 
male mice by four weekly intraperitoneal injections of approximately 50 ×  106 cells prepared from 
the pooled spleens of 6- to 8-wk-old BALB/cJ male mice. 
Virus Assay.  Spleen cell suspensions (20  x  10  ~ cells/ml) were prepared in Eagle's minimal 
essential medium. Aliquots of 0.1 ml, or their 10-fold dilutions, were plated as infectious centers on 
both BALB/cN and NIH Swiss mouse embryo cells, and assayed for virus by the UV-XC procedure 
(6),  modified as previously described (4). 
Results 
GVHR-CAF1  mice, and normal uninjected CAF1 and BALB/cJ male mice, 
were killed at ages ranging from 8 to 84 wk. We tested 209 individual spleen cell 
suspensions, 117 from GVHR-CAF1 mice, 59 from normal uninjected CAF1 mice, 
and 33 from normal uninjected BALB/cJ mice. 
Expression of B-  and N-tropic MuLV in GVHR-CAF~ mice and in normal 
control CAF, mice is shown in Figs. 1 and 2. Both these viruses were detected as 
the  mice aged.  However, viral  expression was considerably accelerated and 
enhanced in the GVHR group where both B- and N-tropic MuLV were detected 
earlier, in a greater proportion of mice, and in higher titer. In the GVHR-CAF1 
mice, B- and N-tropic MuLV appeared 12 and 20 wk earlier, respectively, than 
in the control CAF1 mice (Fig.  1). Not only were the titers of both viruses higher 
in the GVHR mice than in the control group, but the titer of B-tropic MuLV was 
consistently about one log greater than that of N-tropic MuLV (Fig. 2). Another 
distinctive feature in the GVHR mice was the biphasic nature of viral expres- 1062  ARMSTRONG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIG. 2.  Age-related  titer of  B- and N-tropic MuLV  among  CAFI/J  male mice undergoing  a 
graft-versus-host reaction (GVHR-CAFI/J~) and among  normal control CAFJJ male mice 
(NCAF1/J~). Mean titer of B-tropic MuLV (0-0),  of N-tropic (U---B) in spleen cell 
suspensions. Negative: less than two plaque-forming  units (PFU)/2 × l0  s spleen cells. 
sion.  From 12  to 20 wk,  and after a  transient eclipse around 40-44  wk, both 
viruses  rapidly surfaced in a  majority of mice,  quickly gaining substantial 
titers.  Although N-tropic MuLV appeared first in both waves, the titer of B- 
tropic MuLV rose faster and higher. In the control CAF~ group, neither virus 
was detected until 32 wk. Both then followed the same gradual, muted pattern of 
emergence,  without remission,  until 48  wk,  when N-tropic  MuLV began to 
wane. 
Among the  virus-positive mice,  58%  in the  GVHR group  and  63%  in the 
control CAF1 group expressed both B- and N-tropic MuLV. Both types of MuLV 
were deemed to be present in an individual spleen cell suspension if the number 
of infections centers on BALB/cN mouse embryo cells and that on NIH Swiss 
mouse embryo cells showed less than a 50-fold difference. 
Expression  of mouse-tropic MuLV in normal BALB/cJ male mice differed 
from the control CAF~ group in that N-tropic MuLV was first detected rather 
early,  at 20  wk  (Fig.  3).  The percentage  of positive mice rose  quite  slowly, 
however, and did not exceed that in the control CAF~ group. Emergence of B- 
tropic MuLV was similar in both groups of normal mice, as were the titers of 
both viruses, at least until 48 wk. Thereafter, the mean titer of B-tropic MuLV 
rose more steeply in the BALB/c group. 
Four spleen cell suspensions, each prepared from a pool of 12 spleens removed 
from 6- to 8-wk-old BALB/cJ male mice, and used to induce the GVHR in CAF1 
male mice, were also tested for MuLV. All four pools contained neither B- nor N- 
tropic MuLV. 
Discussion 
The cells of mice contain the necessary genetic information to code for the 
constituents of MuLV (7). In mice such as the AKR strain, the appearance of 
infectious MuLV in substantial titer early in postnatal life is associated with a ARMSTRONG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIG.  3.  Age-related appearance  (upper graph) and age-related titer (lower graph)  of B- 
and N-tropic MuLV among normal BALB/cJ male mice (NBALB/cJd).  (. x • ) number of 
mice tested for MuLV.  (e-  e) in upper graph, percentage of mice with B-tropic MuLV; in 
lower graph,  mean  titer of B-tropic MuLV in spleen cell suspensions.  (B---B) in upper 
graph,  percentage  of mice with N-tropic MuLV;  in  lower graph,  mean titer of N-tropic 
MuLV in spleen cell suspensions.  Negative: less than two PFU/2 x  10  6 spleen cells. 
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high spontaneous incidence of lymphoma within a year (8). This high leukemia 
strain is of the Fv-1  n" genotype, and its tumors are caused by endogenous N- 
tropic MuLV (9). 
Evidence that endogenous B-tropic MuLV may also be oncogenic has come 
from study of  BALB/c mice. Here, however, neoplasms are rare before 1 yr of age 
(10). Thereafter, the incidence of tumors increases with age, the commonest of 
the malignant neoplasms being lymphoreticular tumors which occur in 19% of 
BALB/c mice over 2-yr old (10). B-tropic MuLV has been etiologically incrimi- 
nated in the development of these tumors (11). A study of MuLV expression 
during the life-span of BALB/c mice showed that although 90% of mice under 6 
mo were virus negative, the incidence of demonstrable infectious mouse-tropic 
MuLV rose rapidly thereafter (12). Most of the viral isolates before 1 yr were N- 
tropic; isolations of B-tropic MuLV became more frequent in older mice, but only 
after 24 mo did the isolation rate exceed that of N-tropic MuLV (12). 
Our study of MuLV expression in normal and GVHR-CAF, mice shows that 
beth B- and N-tropic MuLV are normally detected after 6 mo of age, but that the 
GVHR accelerates induction of both viruses and preferentially  enhances replica- 
tion of B-tropic MuLV. Since CAF1 mice are of the Fv-1  bb  genotype, B-tropic 
MuLV should replicate more efficiently than N-tropic MuLV (9). It is not clear, 
however, why such preferential replication is not seen in either normal CAF1 
mice or normal BALB/c mice (also of the Fv-1  bb genotype) until relatively late in 
life.  This might reflect greater inducibility of N-tropic MuLV,  coupled with 
resistance to spread of infection, and relative absence of cells in which either 
mouse-tropic MuLV  could  replicate.  Oncornaviruses need dividing cells for 
replication (13). The GVHR provides a large pool of dividing lymphocytes, an 
admixture of donor thymus-derived (T) cells and host bone-marrow-derived (B) 1064  ARMSTRONG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
cells,  recruited  through  allogeneic  activation  (14).  The  dividing  B  cells may 
preferentially replicate the induced viruses, since lipopolysaccharide-stimulated 
B cells do support MuLV growth (15). 
It  is not  known  why two mouse-tropic  MuLV  are  expressed  in  CAFI  and 
BALB/c mice as they age, nor how each virus influences the other. However, the 
earlier appearance and enhanced replication of B-tropic MuLV in GVHR-CAF~ 
mice is probably causally related to induction of tumors, since the same tumors 
are reproduced by serially passaged GVHR extracts containing B-tropic MuLV, 
but no N-tropic MuLV (4). Xenotropic MuLV (16) is not measured in our assay, 
but we are currently studying its possible role in tumor induction. 
In this model, the oncogenic potential of endogenous oncornavirus is revealed 
through an immunological disorder. Dividing cells available early in the GVHR 
may enable endogenous  MuLV to passage  through  successive generations  of 
cells,  resulting  not  only in earlier  and  higher  titers  of infectious  virus,  but 
possibly also in the emergence of oncogenic variants. 
Summary 
Mice of the low leukemia (BALB/cJ x  A/J)F1 hybrid (CAF~) strain express B- 
and N-tropic infectious murine leukemia virus (MuLV) after the age of 6 mo. 
Initiation of a protracted immunological disorder, the graft-versus-host reaction 
(GVHR), at 7 wk of age,  accelerates the induction  of both these mouse-tropic 
endogenous  viruses,  and  preferentially  enhances  the  replication  of B-tropic 
MuLV. The earlier appearance of B-tropic MuLV in a greater proportion of mice 
and in higher titer is thought to be causally related to the eventual development 
of lymphoreticular  tumors  in  the  GVHR  mice,  since  previous  studies  have 
shown  that  these  same  tumors  can  be  reproduced  by inoculating  syngeneic 
recipients with serially passaged GVHR extracts containing B-tropic MuLV. 
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